Publication | Closed Access
A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies
95
Citations
23
References
2018
Year
Avadomide monotherapy demonstrated acceptable safety and favorable pharmacokinetics in patients with solid tumors, NHL, and multiple myeloma. In addition, 3 objective responses were observed in NHL.
| Year | Citations | |
|---|---|---|
Page 1
Page 1